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ABSTRACT
The availabil i ty of research reactors at  an early stage of our Atomic
Energy Programme led to developmental efforts in the field of
radiopharmaceuticals. Starting with temporary laboratories for this
work, a sophisticated and dedicated Radiopharmaceutical Laboratory
is now installed at Vashi in New Bombay.
The use of several ‘25Elabelled  compounds like Rose-Bengal,
hippuran, etc. for imaging has been replaced over the years by *Tc
compounds; the final formulations are prepared at the hospital using
generators and cold kits supplied by the Board of Radioisotope
Technology. Parallel with the development of short-lived generators
in radiopharmaceuticals  came advances in imaging and instrumentation
techniques, the scanners being replaced by sophisticated gamma
cameras,  with capabil i t ies for tomography and computerisation.  About
40 centres in India have the modem instrumentation and equipment
needed for carrying out nuclear medicine procedures. purther growth
of nuclear medicine eentres in the country has, however, been limited
by the need to import such advanced high cost instrumentation not
currently available from indigenous sources. Regarding in-vitro
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radiopharmaceuticals,  some RIA and IRMA kits and procedures have
been developed. These include assay of T3,  T4 and TSH in the thyroid
group of hormones. Kits for several other important procedures are
still being imported by some large medical centres. There are over a
hundred and fifty medical laboratories carrying out RIA procedures.
1. INTRODUCTION
The development of atomic energy in India owes much to the leadership provided
by many dedicated Indian scientists and technologists. It was indeed fortuitous for
India that Dr. Homi Bhabha came on the scientific scene in the fifties, at the time
when Pandit Nehru, himself an ardent believer in science, was the Prime Minister of
India. As a consequence of the mutual trust and admiration they had for each other,
the Atomic Energy Programme (AEP) obtained the right priority and got off with
an early start. The commissioning of the 1 MW swimming pool reactor, APSARA in
1957 and the 40 MW research reactor CIRUS in 1960 gave a great impetus to the
development of nuclear science and technology in India.
The applications of radioisotopes in diverse fields were recognised by the Govt.
of India to be one of the important objectives of the AEP, second only to the production
of the nuclear power. Radioisotopes were already in use ‘for medical applications in
many advanced countries--in particular, ‘131Z  was the single most frequently used
isotope, and was found to be of great benefit in the diagnosis and treatment of thyroid
disorders. Around 1957, I’(V.K. Iya) was given the responsibility to build a self-reliant
production and applications programme for isotopes. Our first task was to set up a
temporary isotope production laboratory in an old and dust-laden textile shed, leased
out from Bombay Dyeing, off Cadell Road in the central part of the Bombay.
It was my (Iya) privilege to come into contact with the young Col. Mazumdar
right in the early stages of the radioisotope programme around 1960, when he was
still at the Safdarjang Hospital. We had just established the production of 131Z  (0.5
to 1 curie per batch), of Colloidal ‘%Au  and, of 32P,  at the Cadell Road Laboratory.
Though the laboratories were ventilat;d  with filtered air and airconditioned, the
surrounding areas were filthy and far from ideal. Entering as we were in a new field
of producing radioactive materials which were to be administered.into  human beings
for medical use, we were naturally hesitant and somewhat diffident about supplying
our products. Mazumdar sensed this and gave me and my colleagues his advice as
well as his unstinted support. He expressed his full confidence in the quality of our
scientific efforts.
In 1960 the Atomic Energy Commission had set up a pavilion in the World
Agricultural Fair. Dr. Homi Bhabha had put me (Iya) in-charge of setting up the
Atomic Energy Exhibit, which included, inter alia, live isotope production laboratory.
This was fitted with glove boxes and lead-shielded remotely operated production
boxes, inside a glass-fronted laboratory so that the public could view the handling of
radioactive materials. The idea was to produce isotopes in a TRIGA  reactor, which
was on display in the US pavilion of exhibition, process them in the isotope laboratory
of the atomic energy pavilion and supply short-lived isotopes to hospitals in Delhi.
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The young Col. Mazumdar wasenthused  by this idea and gave us his full support.
He took me to Safdarjang Hospital to Col. Rao and Cal. Iyer, the big medical names
of that period, who immediately agreed to support our efforts to introduce nuclear
medicine. at the Safdarjang Hospital.
Col. Mazumdar and Dr. Venkatasubramanian (of the Pate1 Chest Institute) saw
our production processes, and, after satisfying themselves about the quality of our
products, used some of these isotopes for clinical applications. In fact Col. Mazumdar
was the first doctor to use colloidal ‘%Au  in India, He was truly a pioneer in nuclear
medicine in India.
The end of the exhibition saw the dismantling of the atomic energy pavilion. I
(Iya) took the liberty of transferring some of the materials like lead bricks, fume
h6ods  and tong-and glove-boxes to the Safdarjang Hospital. Col. Mazumdar hired
some carpenters to put up partitions and we were thus able to set up a functioning
isotope laboratory for nuclear medicine at the Safdarjang Hospital in a few days time.
This ‘radiation cell’ was the first such isotope laboratory for nuclear medicine in the
country. I did not seek any formal government clearances from any authorities. But
Col. Mazumdar and I were partners in a project for the public good and those were
the days when scientists like Bhabha were tall, and bureaucrats did not dare question
them or put any obstacles. We knew that Homi Bhabha would support us fully if any
questions were raised.
A few years later, the Institute of Nuclear Medicine and Allied Sciences (INMAS)
was set up at Probyn Road, Delhi by Col. Mazumdar with the full support of
Dr. Kothari, the then Scientific Adviser to the Defence Minister. This important
project was a pioneering effort and a remarkable achievement set up in record time.
Our scientific collaboration increased and so did our friendship. Mazumdar was a
warm-hearted human. He often invited me (Iya) to Delhi officially to visit his Institute,
and to have discussions with him and his colleagues. None of these visits passed
without my visiting his house in Lytton Lane in the evenings. I often look back with
nostalgic memories at those wonderful evenings, enjoying the hospitality provided by
Mrs. Mazumdar. We relaxed long over our drinks and poured out to each other our
problems and frustrations. These we had in plenty, making for us one more common
bond. Mazumdar was a lovable and generous person. At many scientific meetings,
he was fulsome in his praise of the work of the Isotope Group of BARC. He often
emphasised the pioneering nature of the work of the scientists in the Isotope Group
in establishing a self-reliant programme so early in the country’s developmental efforts.’
All this was possible because we could always depend for advice and support of many
specialists like Col. Mazumdar.
The growth of nuclear medicine in India has been influenced by several factors.
These include the availability of trained manpower, the indigenous development and
production of radiopharmaceuticals, and, of the electronic instrumentation for
imaging, and finally, the availability of the necessary supporting infrastructure in
hospitals. Over the years, the indigenous production of radiopharmaceuticals, with
some exceptions, has generally kept pace with the technological developments
elsewhere.
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2. DEVELOPMENT OF RADIOPHARbiACEUTICALS IN INDIA
2.1 Reactors
Commissioned in 1957, the 1 MW APSARA reactor helped us in the early
research work for isotope development. The CIRUS,  a 40 MW research reactor, was
commissioned in 1960 and has good facilities for the production of most of the isotopes
required in nuclear medicine. This reactor has proved invaluable for the production
of radiopharmaceuticals in the country, and has indeed been the mainstay of the
isotope production and applications programme. Neutron fluxes of upto about
5 X 1013 ncmw2se1 are available and is adequate to achieve the specific activity required
for most isotopes. With the increased facilities available from DHRUVA, the
100 MW research reactor, ,commissioned  in the mid-eighties, neutron flux facilities
may be considered as sufficient to meet the country’s requirement of reactor-produced
isotopes needed for radiopharmaceuticals production.
2.2 Hot Laboratories
Matching with these reactor facilities and also with the progress in the use of
radiopharmaceuticals, increasingly sophisticated laboratories were set up for
radiopharmaceutical production. Starting with the Cadell Road Laboratories initially,
production facilities were transferred in the mid-sixties to the intermediate laboratories
in the South Site at Trombay. At the same time, detailed planning of more advanced
facilities for large scale production was taken up, and as a consequence, the
Radiological Laboratories were commissioned in the early seventies. Full scale
production cells were set up in these laboratories for each of products required, tilohg
with a quality control laboratory for establishing the chemical and radio-chemical
purity of the radiopharmaceuticals. With the setting up of a well equipped animal
house in the Modular Laboratory at Trombay, the Radiopharmaceutical Division of
the Isotope Group was now self-sufficient to carry dut all the biological tests necessary
for ensuringthe quality of the radiopharmaceuticals supplied. One major disadvantage
of the Radiological Laboratories, however, was that these laboratories also housed a
number of other activities, involving the handling of various toxic materials, including
some industrial isotopes, fission products, plutonium and trans-uranium elements.
Taking this into account,’ and’ considering the need for expansion of the
radiopharmaceutical programme’, it was decided to set up more streamlined facilities
to keep pace with advancing concepts in pharmaceutical practices. A new, modern
and dedicated Radiopharmaceutical Laboratory was set up and commissioned in 1985.
This new laboratory, named Isophar& (isotopes for pharmaceuticals) is located at
Vashi, New Bombay, about 15 kms from BARC, Trombay. The laboratory has an
area of about 4000 sq m and is equipped with modem facilities for the handling and
storage of adequate levels of radioactive isotopes on the one hand, and for fulfilling
the requirements of good manufacturing practices necessary for production of
pharmaceutical products, on the other. The hot laboratories and processing plants
are designed to take up the processing of a wide spectrum of isotope products for
medical use, including short-lived generators and their cold kits, without
cross-contamination from other isotopes.
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The Isopharm Laboratory also has a facility for the production and quality control
of radioimmunoassay (RIA) kits, storage of thermolabile antigens, radiolabelling of
multiple batches of different antigens at a time, and freeze drying of RIA reagents.
The routine production and supply of all radiopharmaceutical products including
in viva products (orals and injectables),  generators and kits, RIA kits, and reagents
are made from Isopharm today. A second phase expansion of Isopharm has been
envisaged bearing in mind the need for newer reagents and RIA products and a
Hybridoma Laboratory for the production of monoclonal antibodies. With a view to
providing a nucleus for the growth of applications in different regions of the country,
the Radiopharmaceutical Division also set up two regional centres for radio-
pharmaceuticals, one located at the Kidwai Memorial Institute of Oncology,
Bangalore, and the other at INMAS, Delhi. Apart from these, the Division operates
a regional RIA centre at Dibrugarh and a small radiopharmaceutical laboratory at
Calcutta.
The radiopharmaceutical programme itself now forms a constituent of the Board
of the Radiation and Isotope Technology (BRIT) which was constituted as a separate
unit in the Department of Atomic Energy in March 1988, so that the production and
commercial aspects of the radioisotope programme could be developed to its full
potential.
2.3 Development and Utilisation Pattern of In VivoProducts
The production of several primary isotopes in multicurie quantities, (for example,
13’Z  and 32P  radiopharmaceutical formulations) is currently carried out in the
Radiological Laboratories located in Trombay. Many of the isotopes produced in the
early years of our programme, viz., 24Na, 42K,  “0 etc., for investigations of trace
elements in physiology and haematology have now gone into gradual disuse. The use
of colloidal “*AU for cancer therapy, of ‘03ZZg labelled  neohydrin for kidney and brain
scanning, and the use of many 13iZ labelled  compounds like Rose-Bengal, hippuran,
human serum albumin and other compounds for the scintigraphy of different organs
and the study of different systems, progressively came down. The routine production
of some of these was halted in the late seventies and early eighties, while others came
in the ‘limited production’ list. Their role has largely been taken over by various
labelled  compounds of 99mTc  which has now become the workhorse of nuclear
medicine. Paripassu with these developments in the radiopharmaceuticals field, there
were significant developments in imaging technology. The advent of sophisticated
gamma cameras, on the international scene, capable of imaging different organs, using
the short-lived ggmTc-labelled compounds, led to a rapid decline in the use of scanners.
The emphasis in nuclear medicine has thus veered to the use of 99mTclabelled .
compounds based on structure-activity relation. These labelled  compounds are
generally prepared at the hospital itself usingt ggMo-99mT~  generator systems supplied
along with ‘cold’ kits containing the reagents for preparing the required labelled
formulations. The current technetium compounds most commonly used in the country
include Tc-pertechnetate (thyroid), Tc-MDP (methylene disphosphonate) for skeleton
and bone imaging, Tc-DTPA  (kidney function) and Tc-phytate  and TcS-colloid  (liver
imaging). Current efforts are directed towards the development of 99mT~  alkyl
356 VKZya&  RSMani
isonitriles for cardiac studies. This would obviate the need to import 201n
(a cyclotron-produced isotope) for myocardial perfusion studies. The development of
WmTc-HMPOA  will provide nuclear medicine centres with a suitable agent for brain
perfusion studies.
2.4 In Vitro Products
The two main categories of radiopharmaceutical in vitro products are based on
RIA and the related immuno-radiometrie assay (IRMA) techniques. Both are highly
sensitive and specific analytical techniques, enabling the quantitative measurement of
molecules like hormones, drugs, metabolites, etc., in body fluids and biological
samples. The techniques based on an antibody-antigen reaction-derive their
specificity from the use of antibodies, while the sensitivity is mainly due to the use
of a radioisotope (usually ‘25Z iodine-125) as tracer.
A number of RIA kits and procedures have been developed by BARCZBRIT
scientists, and are in regular use in over a hundred centres in the country. These
include kits for the assay of the thyroid group of hormones, T3, T4  and TSH, and
some others like HCG, insulin, etc. Apart from these, a number of other RIA
procedures, using imported kits, are in regular use in some of the larger and more
advanced medical laboratories.
A number of tumour markers like CEA, AFP, PAP, CA125, CA 19-9, etc. are
currently available in the international market and are being increasingly used for the
early detection and follow-up in the diagnosis and treatment of different types of
cancer. The use of monoclonal antibodies combined with a wide range of new
separation and detection procedures have led to the increasing use of in vitro RIA,
IRMA and ELISA techniques. Development efforts in India will need to be directed
on a time-targeted basis towards these recent advances, if we are to catch up with
this technology in the country.
2.5 Manpower Developmqmt
A large number of useful training programmes have been instituted by BARC
and other institutions. These include specialised training in nuclear. medicine,
radioisotope technology, medical physics, hospital pharmacy and RIA techniques.
Regarding RIA, however, there is need to consider the formulation of a more indepth
and comprehensive training programme comparable with those in western countries
so that the use of in vitro techniques may grow on the right lines and be used more
effectively for medical diagnosis in India.
3. CONCLUSION
In conclusion, we may note that the dedicated work of scientists in BARCBRIT
in close cooperation with eminent specialists and pioneers in other nuclear medicine
centres over the years has led to the early development of nuclear medicine in the
country. This growth has however been limited, owing to several factors, especially
the inadequate infrastructural support provided by the government and hospitals, and
the lack of advanced gamma cameras for imaging. There are only about 40 gamma
cameras in the whole country, compared to about 300 in France and 8000 in USA.
Finally a time targeted programme for the development of RIA kits would be of great
support to the growth of nuclear medicine in the country.
